Efficacy and Safety of Intravenous Peramivir for Treatment of Seasonal Influenza Virus Infection

被引:117
作者
Kohno, Shigeru [1 ]
Kida, Hiroshi [2 ]
Mizuguchi, Masashi [3 ]
Shimada, Jingoro [4 ]
机构
[1] Nagasaki Univ, Sch Med, Dept Internal Med 2, Nagasaki 8528501, Japan
[2] Hokkaido Univ, Dept Dis Control, Grad Sch Vet Med, Sapporo, Hokkaido, Japan
[3] Univ Tokyo, Grad Sch Med, Dept Dev Med Sci, Tokyo, Japan
[4] St Marianna Univ, Sch Med, Kawasaki, Kanagawa, Japan
关键词
NEURAMINIDASE; OSELTAMIVIR; ZANAMIVIR; HOSPITALIZATION; RESISTANCE; PNEUMONIA; THERAPY; MICE;
D O I
10.1128/AAC.00474-10
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Peramivir, a sialic acid analogue, is a selective inhibitor of neuraminidases produced by influenza A and B viruses. We evaluated the efficacy and safety of a single intravenous dose of peramivir in outpatients with uncomplicated seasonal influenza virus infection. A total of 300 previously healthy adult subjects aged 20 to 64 years with a positive influenza virus rapid antigen test were recruited within 48 h of the onset of influenza symptoms and randomized to three groups: single intravenous infusion of either 300 mg peramivir per kg of body weight, 600 mg peramivir, or matching placebo on study day 1. Influenza symptoms and body temperature were self-assessed for 14 days. Nasal and pharyngeal swabs were collected to determine the viral titer. The primary endpoint was the time to alleviation of symptoms. Of the 300 subjects, 296 were included in the intent-to-treat infected population (300 mg peramivir, n = 99; 600 mg peramivir, n = 97; and placebo, n = 100). Peramivir significantly reduced the time to alleviation of symptoms at both 300 mg (hazard ratio, 0.681) and 600 mg (hazard ratio, 0.666) compared with placebo (adjusted P value, 0.0092 for both comparisons). No serious adverse events were reported. Peramivir was well tolerated, and its adverse-event profile was similar to that of placebo. A single intravenous dose of peramivir is effective and well tolerated in subjects with uncomplicated seasonal influenza virus infection.
引用
收藏
页码:4568 / 4574
页数:7
相关论文
共 26 条
[1]  
Abdel-Ghafar AN, 2008, NEW ENGL J MED, V358, P261, DOI 10.1056/NEJMra0707279
[2]  
[Anonymous], DIV AIDS TABL GRAD S
[3]  
[Anonymous], 2007, WEEKLY EPIDEMIOLOGIC, V82, P41
[4]   Anti-influenza virus activity of peramivir in mice with single intramuscular injection [J].
Bantia, S ;
Arnold, CS ;
Parker, CD ;
Upshaw, R ;
Chand, P .
ANTIVIRAL RESEARCH, 2006, 69 (01) :39-45
[5]   The Emergency Use Authorization of Peramivir for Treatment of 2009 H1N1 Influenza [J].
Birnkrant, Debra ;
Cox, Edward .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (23) :2204-2207
[6]   Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern [J].
Bright, RA ;
Medina, MJ ;
Xu, XY ;
Perez-Oronoz, G ;
Wallis, TR ;
Davis, XHM ;
Povinelli, L ;
Cox, NJ ;
Klimov, AI .
LANCET, 2005, 366 (9492) :1175-1181
[7]   Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide [J].
Deyde, Varough M. ;
Xu, Xiyan ;
Bright, Rick A. ;
Shaw, Michael ;
Smith, Catherine B. ;
Zhang, Ye ;
Shu, Yuelong ;
Gubareva, Larisa V. ;
Cox, Nancy J. ;
Klimov, Alexander I. .
JOURNAL OF INFECTIOUS DISEASES, 2007, 196 (02) :249-257
[8]   Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants [J].
Gubareva, LV ;
Webster, RG ;
Hayden, FG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (12) :3403-3408
[9]   Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections [J].
Hayden, FG ;
Osterhaus, ADME ;
Treanor, JJ ;
Fleming, DM ;
Aoki, FY ;
Nicholson, KG ;
Bohnen, AM ;
Hirst, HM ;
Keene, O ;
Wightman, K .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (13) :874-880